The stock of Regulus Therapeutics Inc (NASDAQ:RGLS) hit a new 52-week low and has $2.15 target or 13.00% below today’s $2.47 share price. The 6 months bearish chart indicates high risk for the $121.39M company. The 1-year low was reported on Nov, 4 by Barchart.com. If the $2.15 price target is reached, the company will be worth $15.78M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 201,199 shares traded hands. Regulus Therapeutics Inc (NASDAQ:RGLS) has declined 68.39% since April 4, 2016 and is downtrending. It has underperformed by 69.48% the S&P500.
Regulus Therapeutics Inc (NASDAQ:RGLS) Ratings Coverage
Out of 5 analysts covering Regulus Therapeutics (NASDAQ:RGLS), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Regulus Therapeutics has been the topic of 10 analyst reports since August 5, 2015 according to StockzIntelligence Inc. Wedbush maintained Regulus Therapeutics Inc (NASDAQ:RGLS) on Wednesday, August 5 with “Buy” rating. The stock of Regulus Therapeutics Inc (NASDAQ:RGLS) earned “Buy” rating by Chardan Capital Markets on Tuesday, June 28. The rating was maintained by Needham on Wednesday, November 2 with “Buy”. On Tuesday, June 7 the stock rating was maintained by Chardan Capital Markets with “Buy”. BMO Capital Markets initiated Regulus Therapeutics Inc (NASDAQ:RGLS) rating on Tuesday, April 12. BMO Capital Markets has “Outperform” rating and $16 price target. Wells Fargo initiated the shares of RGLS in a report on Friday, December 4 with “Outperform” rating. Chardan Capital Markets initiated the stock with “Buy” rating in Wednesday, April 13 report. On Tuesday, June 28 the stock rating was downgraded by BMO Capital Markets to “Market Perform”. Needham maintained Regulus Therapeutics Inc (NASDAQ:RGLS) rating on Tuesday, June 28. Needham has “Buy” rating and $10 price target.
According to Zacks Investment Research, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California.”
Insitutional Activity: The institutional sentiment increased to 1.23 in 2016 Q2. Its up 0.19, from 1.04 in 2016Q1. The ratio is positive, as 26 funds sold all Regulus Therapeutics Inc shares owned while 14 reduced positions. 6 funds bought stakes while 43 increased positions. They now own 27.05 million shares or 18.99% less from 33.39 million shares in 2016Q1.
California State Teachers Retirement Systems has 0% invested in the company for 81,343 shares. Tocqueville Asset Management L P has invested 0% of its portfolio in Regulus Therapeutics Inc (NASDAQ:RGLS). Bourgeon Cap Mngmt Ltd Liability Corporation reported 70,704 shares or 0.13% of all its holdings. Teacher Retirement Systems Of Texas last reported 4,371 shares in the company. The New York-based American Intl Group Incorporated has invested 0% in Regulus Therapeutics Inc (NASDAQ:RGLS). Bnp Paribas Arbitrage last reported 0% of its portfolio in the stock. South Dakota Investment Council holds 0.06% or 900,000 shares in its portfolio. Metropolitan Life Insurance Ny has 32,051 shares for 0% of their US portfolio. Proshare Advisors Limited Liability holds 0% of its portfolio in Regulus Therapeutics Inc (NASDAQ:RGLS) for 44,037 shares. Ladenburg Thalmann Financial Svcs accumulated 2,000 shares or 0% of the stock. Columbia Prns L L C Inv holds 0.08% of its portfolio in Regulus Therapeutics Inc (NASDAQ:RGLS) for 389,144 shares. Aperio Ltd Company accumulated 11,360 shares or 0% of the stock. Swiss Bancorp reported 58,200 shares or 0% of all its holdings. California Pub Employees Retirement Sys accumulated 0% or 208,100 shares. One Trading L P accumulated 51,957 shares or 0% of the stock.
More important recent Regulus Therapeutics Inc (NASDAQ:RGLS) news were published by: Fool.com which released: “Regulus Therapeutics Inc. Clinical Hold: Should Investors Be Yellow-Bellied?” on June 28, 2016, also Fool.com published article titled: “Why Regulus Therapeutics Inc. Fell 20.1% in April”, Marketwatch.com published: “Regulus Therapeutics’ stock set to fall after FDA places hepatitis C treatment …” on June 27, 2016. More interesting news about Regulus Therapeutics Inc (NASDAQ:RGLS) was released by: Marketwatch.com and their article: “Regulus Therapeutics stock surges after ‘promising’ Hep C drug trial results” with publication date: February 17, 2016.
RGLS Company Profile
Regulus Therapeutics Inc., incorporated on September 5, 2007, is a biopharmaceutical firm focused on discovering and developing drugs that target microribonucleic acid (microRNAs) to treat a range of diseases. The Firm uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical firm to explore microRNAs as biomarkers for specific patient populations.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.